Skip to Content

In studies, by how long does Lonsurf increase survival?

Answers (1)

Official Answer by Drugs.com 9 Mar 2016

Lonsurf (generic names: trifluridine and tipiracil) is approved for patients with advanced (metastatic) colorectal cancer who are no longer responding to other therapies, such as chemotherapy and biological therapy.

Lonsurf is a nucleoside metabolic inhibitor which is incorporated directly into DNA and interferes with its function. The blood level of trifluridine is maintained by the enzyme inhibitor tipiracil.

In clinical studies, patients treated with Lonsurf lived an average of 7.1 months compared to 5.3 months for those treated with placebo (a sugar pill). On average, the time to cancer progression was two months for patients on Lonsurf compared to 1.7 months for patients receiving placebo.

Common side effects with Lonsurf include anemia, neutropenia (low white blood cells), thrombocytopenia (low blood platelets), physical weakness, extreme tiredness and lack of energy (fatigue).

Votes: +0
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of cancer is Rubraca used to treat?

Posted 8 Feb 2017 1 answerFAQ by Drugs.com

How is Spinraza administered?

Posted 8 Feb 2017 1 answerFAQ by Drugs.com

How is Arymo ER formulated to be abuse deterrent?

Posted 8 Feb 2017 1 answerFAQ by Drugs.com

How is Vantrela ER formulated to be abuse deterrent?

Posted 8 Feb 2017 1 answerFAQ by Drugs.com

How does Trulance work?

Posted 8 Feb 2017 1 answerFAQ by Drugs.com